Cellular & Molecular Biology Letters (Apr 2023)

Blood-based liquid biopsy: insights into early detection, prediction, and treatment monitoring of bladder cancer

  • Shijie Li,
  • Kerong Xin,
  • Shen Pan,
  • Yang Wang,
  • Jianyi Zheng,
  • Zeyu Li,
  • Xuefeng Liu,
  • Bitian Liu,
  • Zhenqun Xu,
  • Xiaonan Chen

DOI
https://doi.org/10.1186/s11658-023-00442-z
Journal volume & issue
Vol. 28, no. 1
pp. 1 – 37

Abstract

Read online

Abstract Bladder cancer (BC) is a clinical challenge worldwide with late clinical presentation, poor prognosis, and low survival rates. Traditional cystoscopy and tissue biopsy are routine methods for the diagnosis, prognosis, and monitoring of BC. However, due to the heterogeneity and limitations of tumors, such as aggressiveness, high cost, and limited applicability of longitudinal surveillance, the identification of tumor markers has attracted significant attention in BC. Over the past decade, liquid biopsies (e.g., blood) have proven to be highly efficient methods for the discovery of BC biomarkers. This noninvasive sampling method is used to analyze unique tumor components released into the peripheral circulation and allows serial sampling and longitudinal monitoring of tumor progression. Several liquid biopsy biomarkers are being extensively studied and have shown promising results in clinical applications of BC, including early detection, detection of microscopic residual disease, prediction of recurrence, and response to therapy. Therefore, in this review, we aim to provide an update on various novel blood-based liquid biopsy markers and review the advantages and current limitations of liquid biopsy in BC therapy. The role of blood-based circulating tumor cells, circulating tumor DNA, cell-free RNA, exosomes, metabolomics, and proteomics in diagnosis, prognosis, and treatment monitoring, and their applicability to the personalized management of BC, are highlighted.

Keywords